X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ImmunoBody® vaccines are designed to induce potent cytotoxic CD8 T cell responses against multiple epitopes via a dual mechanism of action. These DNA vaccines are being used both for the treatment of cancer.
Lead Product(s): SCIB1,Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: SCIB1
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Recipient: PharmaJet
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
Covidity (SCOV1 and SCOV2 vaccine), administered via needle-free intradermal injection, is a prophylactic DNA vaccine produces a durable immunity against the SARS-CoV-2 virus.
Lead Product(s): SCOV1,SCOV2
Therapeutic Area: Infections and Infectious Diseases Product Name: COVIDITY
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: PharmaJet
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
Modi-1 vaccine comprises three citrullinated peptides, two derived from vimentin and one from α-enolase, peptides from two different proteins have been combined in this way to reduce the possibility of tumour escape by activating CD4 cells.
Lead Product(s): Modi-1,Pembrolizumab
Therapeutic Area: Oncology Product Name: Modi-1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
Covidity (plasmid DNA vaccine), administered via needle-free intradermal injection, is a prophylactic DNA vaccine produces a durable immunity against the SARS-CoV-2 virus.
Lead Product(s): Plasmid DNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: COVIDITY
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
SCOV1 and SCOV2 are based on a modification of Scancell's ImmunoBody® DNA vaccine technology to induce high avidity T-cell immune responses against both N and S viral antigens. COVIDITY clinical trial assess safety and immunogenicity of SCOV1 and SCOV2.
Lead Product(s): SCOV1,SCOV2
Therapeutic Area: Infections and Infectious Diseases Product Name: Covidity
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: University of Cape Town Lung Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2021
Details:
SN14 also incorporates Scancell’s AvidiMab™ technology to further enhance this immune response demonstrating the broad potential of this platform technology to generate improved vaccines for both infectious diseases and cancer.
Lead Product(s): SN14
Therapeutic Area: Infections and Infectious Diseases Product Name: SN14
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2020
Details:
The funding will be used to initiate a Phase 1 clinical trial (“COVIDITY”) during 2021. Scancell’s DNA vaccines target dendritic cells to stimulate high avidity T cells that identify and destroy diseased cells.
Lead Product(s): Covid 19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Innovate UK
Deal Size: $2.6 million Upfront Cash: Undisclosed
Deal Type: Funding August 27, 2020
Details:
Scancell has developed DNA vaccines that target dendritic cells to stimulate high avidity T cells that survey and destroy diseased cells.
Lead Product(s): DNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2020
Details:
Scancell will initiate the US arm of the Phase 2 clinical trial of SCIB1 in patients with metastatic melanoma, receiving the checkpoint inhibitor pembrolizumab, using Ichor’s TriGrid® .
Lead Product(s): SCIB1
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
